TheraRadar
← Back
Data updated: Mar 29, 2026

SIGMAPHARM LABS LLC

CardiovascularInfectious DiseaseRespiratory
Generics

SIGMAPHARM LABS LLC is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Respiratory.

2009
Since
17
Drugs
-
Trials
60
Approved (2yr)

Key Drugs

GRISEOFULVIN,ULTRAMICROSIZE
griseofulvin, ultramicrosize
· 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

SODIUM PHENYLBUTYRATE 2026-02-17
AMBRISENTAN 2026-02-17
Labeling
AMBRISENTAN 2026-02-17
Labeling
AMBRISENTAN 2026-01-18
Labeling
AMBRISENTAN 2026-01-18
Labeling
PROTRIPTYLINE HYDROCHLORIDE 2026-01-07
Labeling
POTASSIUM CHLORIDE 2025-12-22
NITROGLYCERIN 2025-12-18
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 33%
2 drugs
Infectious Disease 33%
2 drugs
Respiratory 17%
1 drugs
Immunology 17%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular, Immunology, Respiratory
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
Johnson & Johnson big-pharma
Immunology, Infectious Disease, Cardiovascular
GSK big-pharma
Infectious Disease, Respiratory, Immunology
Sanofi big-pharma
Infectious Disease, Immunology, Respiratory